Epkinly Approved for Relapsed, Refractory Diffuse Large B-Cell Lymphoma
Epkinly (epcoritamab-bysp) is approved to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after 2 or more lines of systemic therapy.